Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma

To our knowledge, there have been no reports of first-line lenvatinib (LEN) and LEN re-challenge following atezolizumab/bevacizumab (Atezo-Bev) failure in the same patient. We herein report a patient with advanced hepatocellular carcinoma who failed either 1st line LEN and 2nd line Atezo-Bev, and su...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosaka, Yumi, Kawaoka, Tomokazu, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Murakami, Serami, Johira, Yusuke, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ohno, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Imamura, Michio, Aikata, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332959/
https://www.ncbi.nlm.nih.gov/pubmed/36328580
http://dx.doi.org/10.2169/internalmedicine.9581-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332959/
https://www.ncbi.nlm.nih.gov/pubmed/36328580
http://dx.doi.org/10.2169/internalmedicine.9581-22

Ejemplares similares